US 12201617
HDAC6 inhibitors for treatment of metabolic disease and HFpEF
granted A61KA61K31/17A61K31/42
Quick answer
US patent 12201617 (HDAC6 inhibitors for treatment of metabolic disease and HFpEF) held by Tenaya Therapeutics, Inc. expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Tenaya Therapeutics, Inc.
- Grant date
- Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 29
- CPC classes
- A61K, A61K31/17, A61K31/42, A61K31/4245, A61K31/427